Clinical Trials Logo

Clinical Trial Summary

Multicentre, multinational, prospective randomised, open-label, 3 sequence crossover phase III b clinical trial with blinded endpoint assessment (PROBE-design) - in 75 patients with sporadic small vessel diseases (SVDs) and - in 30 patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)


Clinical Trial Description

TREAT-SVDs will be carried out as a multicentre open label trial at five trial sites across 3 European countries: Germany, the Netherlands, and the United Kingdom. Patients meeting eligibility criteria will be randomly allocated to one of three sequences of antihypertensive treatment which are given as open-label oral medications in standard dose in the following order Arm A: Amlodipine > Losartan > Atenolol Arm B: Atenolol > Amlodipine > Losartan Arm C: Losartan > Atenolol > Amlodipine. The study starts with a two week run-in phase. During these first two weeks, patients are not allowed to take antihypertensive drugs except for the rescue medication. After the run-in period,every patient will take subsequently three different antihypertensive drugs (each drug from a separate drug class) according to the randomly assigned arm. Each study drug will be administered for four weeks. Patients will be monitored telemetrically with a dedicated BP device during the whole trial period of 14 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03082014
Study type Interventional
Source Ludwig-Maximilians - University of Munich
Contact
Status Terminated
Phase Phase 3
Start date February 22, 2018
Completion date July 28, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04041349 - Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease Phase 4
Recruiting NCT04109963 - Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment Phase 2
Not yet recruiting NCT05967728 - Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care Phase 2
Completed NCT05714813 - Circuit Training and Retina N/A
Not yet recruiting NCT06077305 - A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke
Not yet recruiting NCT06061692 - Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study(TOPS-CSVD) Phase 4
Recruiting NCT04962295 - China Imaging-based Biobank of Cerebral Small Vessal Diseases
Completed NCT02801032 - Effect of Tadalafil on Cerebral Large Arteries in Stroke Phase 2
Not yet recruiting NCT05594966 - Neuroimaging Combining Biomarkers for Identifying Long-term Cognitive Dysfunction and Delirium
Terminated NCT02890888 - Effect of Hyperbaric Oxygen on Functional Connectivity in Patients With Cerebral Small Vessel Disease N/A
Recruiting NCT04318119 - Cerebral Small Vessel Disease Registry Study
Recruiting NCT03906123 - The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia N/A
Recruiting NCT05306834 - Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease N/A
Not yet recruiting NCT05583266 - Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM) Phase 4
Recruiting NCT05173896 - Improving Cerebral Blood Flow and Cognition in Patients With Cerebral Small Vessel Disease. The ETLAS-2 Trial Phase 2
Recruiting NCT01819441 - Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Phase 4
Recruiting NCT01688505 - Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function N/A
Recruiting NCT04330222 - Cambridge 7 Tesla Cerebral Small Vessel Disease Study
Recruiting NCT04298866 - White Matter Hyperintensities Subtypes in Cerebral Small Vessel Disease : 7 Tesla Ultra-high Resolution Imaging MRI N/A
Not yet recruiting NCT06301711 - Investigation of Potential Mechanisms in Stellate Ganglion Block in Individuals With Cerebral Small Vessel Disease N/A